中国银河证券股份有限公司 关于国新健康保障服务集团股份有限公司 2024 年度内部控制评价报告的核查意见 中国银河证券股份有限公司（以下简称"银河证券"）作为国新健康保障服 务集团股份有限公司（以下简称"国新健康""公司"）2022 年向特定对象发行 股票并在主板上市的保荐机构，根据《深圳证券交易所股票上市规则》《深圳证 券交易所上市公司自律监管指引第 1 号——主板上市公司规范运作》等相关规定， 对国新健康 2024 年度内部控制评价报告进行了审慎核查，具体核查情况如下： 一、内部控制评价结论 根据公司财务报告内部控制重大缺陷和重要缺陷的认定情况，截至内部控制 评价报告基准日，公司不存在财务报告内部控制重大缺陷和重要缺陷。董事会认 为，公司已按照企业内部控制规范体系和相关规定的要求在所有重大方面保持了 有效的财务报告内部控制。 根据公司非财务报告内部控制重大缺陷和重要缺陷认定情况，截至内部控制 评价报告基准日，公司未发现非财务报告内部控制重大缺陷和重要缺陷。自内部 控制评价报告基准日至内部控制评价报告发出日之间未发生影响内部控制有效 性评价结论的因素。 二、内部控制评价范围 公司按照风险导向原则确定纳入评价 ...

证券简称：国新健康 证券代码：000503 编号：2025-25 国新健康保障服务集团股份有限公司 关于变更募集资金用途的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 国新健康保障服务集团股份有限公司（以下简称"公司"或"国新健康"） 于2025年4月23日召开第十一届董事会第三十八次会议暨2024年度会议和第十一 届监事会第二十八次会议暨2024年度会议，审议通过了《关于变更募集资金用途 的议案》，董事会和监事会均同意公司根据最新战略规划及相关募集资金投资项 目（简称"募投项目"）的建设进展等情况，变更部分募集资金用途。本次募投 项目变更事项不涉及关联交易及重大收购，尚需提交股东大会审议，具体情况如 下： 一、变更募投项目的概述 （一）募集资金基本情况 中国证券监督管理委员会《关于同意国新健康保障服务集团股份有限公司向 特定对象发行股票注册的批复》（证监许可〔2023〕1899号），同意公司向特定 对象发行股票的注册申请，公司本次向特定对象发行股票80,413,268股，发行价 格为9.88元/股。根据大信会计师事务所（特殊普通合伙）出具的《国新健康 ...

国新健康保障服务集团股份有限公司 2024 年度 关于国新集团财务有限责任公司风险持续评估报告 根据《深圳证券交易所上市公司自律监管指引第 7 号— —交易与关联交易》《关于规范上市公司与企业集团财务公 司业务往来的通知》要求，国新健康保障服务集团股份有限 公司（以下简称公司）通过查验国新集团财务有限责任公司 （以下简称财务公司）《金融许可证》《营业执照》等证件 资料，审阅财务公司 2024 年年度财务报告，对财务公司的经 营资质、内控制度建设、业务和风险状况及经营情况进行了 评估。现将有关情况报告如下： 一、财务公司基本情况 财务公司成立于 2018 年 5 月 8 日，注册资本人民币 20 亿元，法定代表人纪委，注册地址为北京市海淀区复兴路 12 号恩菲大厦 B 座一层西侧。财务公司是经国家金融监督管理 总局北京监管局批准，由中国国新控股有限责任公司为提升 财务管控效率，丰富国有资本运营试点内容而全资设立的非 银行金融机构。 金融许可证机构编码:L0262H211000001。 统一机构信用代码证号：91110108MA01C0J55L。 经国家金融监督管理总局北京监管局批准的经营业务 范围如下： （一） ...

国新健康保障服务集团股份有限公司 董事会审计委员会对会计师事务所 2024 年度履职情况评估 及履行监督职责情况的报告 根据《中华人民共和国公司法》《中华人民共和国证券法》《上市公司治理 准则》《国有企业、上市公司选聘会计师事务所管理办法》《深圳证券交易所上 市公司自律监管指引第 1 号——主板上市公司规范运作》等法律法规、规范性文 件和《国新健康保障服务集团股份有限公司章程》（以下简称《公司章程》）等 的规定和要求，国新健康保障服务集团股份有限公司（以下简称"公司"）董事 会审计委员会本着勤勉尽责的原则，恪尽职守，认真履职。现将审计委员会对中 证天通会计师事务所（特殊普通合伙）2024 年度履职评估及履行监督职责的情 况汇报如下： 一、2024 年度会计师事务所基本情况 （一）会计师事务所基本情况 会计师事务所名称：中证天通会计师事务所（特殊普通合伙） 成立日期：2014 年 1 月 2 日 组织形式：特殊普通合伙 注册地址：北京市海淀区西直门北大街甲 43 号 1 号楼 13 层 1316-1326 首席合伙人：张先云 截止 2024 年度末合伙人 62 人，注册会计师 378 人，签署过证券服务业务审 ...

等金融业务的专项说明 目 录 关于国新健康保障服务集团股份有限公司涉 及财务公司关联交易的存款、贷款等金融业 务的专项说明 1-2 国新健康保障服务集团股份有限公司 2024 年 度通过国新集团财务有限责任公司存款、贷 款等金融业务汇总表 3 关于国新健康保障服务集团股份有限公司 涉及财务公司关联交易的存款、贷款 中证天通会计师事务所（特殊普通合伙） 中证天通会计师事务所 （特殊普通合伙） 中国·北京 海淀区西直门北大街 43 号 金运大厦 B 座 13 层 邮编 100044 电话 010 6221 2990 传真 010 6225 4941 网址 www.zzttcpa.com 关于国新健康保障服务集团股份有限公司 涉及财务公司关联交易的存款、贷款等 金融业务的专项说明 中证天通（2025）证审字 21190003 号-5 国新健康保障服务集团股份有限公司全体股东： 我们接受国新健康保障服务集团股份有限公司（以下简称"国新健康公 司"）委托，根据中国注册会计师执业准则审计了国新健康公司 2024 年 12 月 31 日的合并及母公司资产负债表，2024 年度合并及母公司利润表、合并及母 公司现金流量表、合 ...

国新健康保障服务集团股份有限公司 监事会 2024 年度工作报告 2024 年度，国新健康保障服务集团股份有限公司（以下简称"公司"）监 事会按照《中华人民共和国公司法》（以下简称《公司法》）《国新健康保障服 务集团股份有限公司章程》（以下简称《公司章程》）及公司《监事会议事规则》 的相关规定，认真地履行监察督促职能，在建立健全公司管理制度、提升公司治 理水平、维护公司及股东合法权益等工作中发挥了应有的作用，现将 2024 年度 监事会工作报告如下： 一、监事会会议召开情况 2024 年共召开 11 次监事会会议，共审议通过 24 项议案，议案涉及公司定 期报告相关事项、募集资金管理与使用事项、回购注销部分限制性股票事项、补 选监事等。会议的召开程序均符合《公司法》等法律法规以及《公司章程》的相 关规定，会议形成的决议合法、有效。具体情况如下： | 序号 | 召开时间 | 会议届次 | 议案 | | --- | --- | --- | --- | | 1 | 2024年1月 | 第十一届监事会第 | 关于使用募集资金置换预先投入的自筹资金的 | | | 12 日 | 十四次会议 | 议案 | | 2 | 20 ...

国新健康保障服务集团股份有限公司 董事会 2024 年度工作报告 2024 年度，国新健康保障服务集团股份有限公司（以下简称"公司"）董 事会按照《中华人民共和国公司法》（以下简称《公司法》）《国新健康保障服 务集团股份有限公司章程》（以下简称《公司章程》）及《董事会议事规则》的 相关规定，切实履行职责，勤勉尽责，强化执行，圆满完成了各项工作，进一步 规范、优化了公司法人治理结构，确保董事会科学决策和规范运作，为保障公司 和全体股东利益、推动公司持续健康发展发挥了重要作用，现将 2024 年度董事 会工作报告如下： 一、董事会会议召开情况 2024 年度，共召开 12 次董事会会议，共审议通过 51 项议案，议案涉及修 订及制定公司治理制度、募集资金使用与管理、关联交易、定期报告、向银行申 请综合授信额度、回购注销限制性股票、补选董事、变更法定代表人、调整公司 架构、聘任会计师事务所等事项。会议的召开程序均符合《公司法》等法律法规 以及《公司章程》的相关规定，会议形成的决议合法、有效。具体情况如下： | 序号 | 召开时间 | | 会议届次 | 议案 | | --- | --- | --- | --- | - ...

国新健康保障服务集团股份有限公司 2024 年度募集资金年度存放与使用情况专项报告 根据中国证监会发布的《上市公司监管指引第 2 号——上市公司募集资金管 理和使用的监管要求》（证监会公告[2012]44 号）和深圳证券交易所发布的《深 圳证券交易所上市公司自律监管指引第 1 号——主板上市公司规范运作》等有关 规定，国新健康保障服务集团股份有限公司（以下简称"公司"或"本公司"）董事 会编制了截至 2024 年 12 月 31 日止的募集资金年度存放与实际使用情况的专项 报告。 一、募集资金基本情况 中国证券监督管理委员会于 2023 年 8 月 23 日出具了《关于同意国新健康保 障服务集团股份有限公司向特定对象发行股票注册的批复》（证监许可〔2023〕 1899 号），同意公司向特定对象发行股票的注册申请。 公司本次向特定对象发行股票 80,413,268 股，发行价格为 9.88 元/股。根据 大信会计师事务所（特殊普通合伙）出具的《国新健康保障服务集团股份有限公 司向特定对象发行股票募集资金验资报告》（23-00006 号），截至 2023 年 11 月 17 日止，公司向特定对象实际发行 A 股股 ...

Financial Performance - The company's revenue for Q1 2025 was ¥50,467,725.80, representing a 5.33% increase compared to ¥47,915,544.20 in the same period last year[3]. - The net profit attributable to shareholders was -¥45,576,538.97, a decrease of 12.86% from -¥40,381,786.35 year-over-year[3]. - The total operating revenue for the current period is CNY 50,467,725.80, an increase from CNY 47,915,544.20 in the previous period, representing a growth of approximately 5.5%[24]. - The net profit for the current period is -45,576,538.97, compared to -40,380,236.63 in the previous period, indicating a decline of approximately 12.5%[25]. - The total comprehensive income for the current period is -45,593,839.33, compared to -40,355,707.49 in the previous period, reflecting a decrease of about 13.5%[25]. - The basic and diluted earnings per share for the current period are both -0.0465, compared to -0.0412 in the previous period, indicating a worsening of approximately 8.0%[26]. Cash Flow and Assets - The net cash flow from operating activities improved by 34.66%, reaching -¥65,632,343.86 compared to -¥100,443,543.19 in the previous year[3]. - The company's cash and cash equivalents decreased to CNY 365,780,927.32 from CNY 451,840,676.26, a decline of about 19%[20]. - Cash and cash equivalents at the end of the period stand at 351,391,328.46, down from 816,969,617.12 at the end of the previous period, a decrease of about 56.9%[27]. - The operating cash flow for the current period is -65,632,343.86, an improvement from -100,443,543.19 in the previous period, showing a reduction in cash outflow by approximately 34.7%[26]. Assets and Liabilities - Total assets decreased by 3.35% to ¥1,992,785,005.50 from ¥2,061,938,679.96 at the end of the previous year[3]. - The total assets of the company as of March 31, 2025, are CNY 1,992,785,005.50, down from CNY 2,061,938,679.96 at the beginning of the period, reflecting a decrease of approximately 3.3%[22]. - The total liabilities decreased to CNY 632,772,661.63 from CNY 656,332,496.76, a reduction of about 3.6%[22]. - The company's total equity decreased to CNY 1,360,012,343.87 from CNY 1,405,606,183.20, indicating a decline of approximately 3.2%[22]. Investments and Expenses - Investment income surged by 212.51% to ¥4,320,158.46, attributed to the growth in net profits of joint ventures and interest income from large bank deposits[8]. - The total operating costs for the current period amount to CNY 101,542,262.28, up from CNY 90,887,714.68 in the previous period, indicating an increase of about 11.5%[24]. - Sales expenses increased by 35.28% to ¥14,923,130.53, reflecting higher investments in market development and sales personnel costs[8]. - The company incurred credit impairment losses of 3,398,061.31, which is significantly higher than 1,795,408.37 in the previous period, marking an increase of approximately 89.2%[25]. Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 70,199[10]. - The largest shareholder, China Oceanwide Holdings Group Co., Ltd., holds 24.02% of the shares, totaling 235,702,593 shares[10]. Corporate Governance - The company appointed Mr. Zhang Zhenhua as the vice president, effective immediately upon board approval[14]. - The company held a board meeting to elect candidates for the twelfth board of directors, including both independent and non-independent directors[15]. - The company has elected a new employee representative supervisor, Ms. Xia Kun, to join the newly formed 12th Supervisory Board[17]. - The company has proposed the nomination of two shareholder representative supervisors for the 12th Supervisory Board, pending approval[16]. - The company approved the repurchase and cancellation of 125,800 restricted stocks due to three individuals no longer meeting incentive conditions[13]. Organizational Changes - The company restructured its organization by dissolving the PBG Data R&D Department and establishing an AI Center to oversee AI infrastructure development[14]. - The company decided to continue using RMB 450 million of temporarily idle raised funds for cash management until January 28, 2026[13].

Financial Performance - The company's operating revenue for 2024 was CNY 356,896,420.31, representing an increase of 8.11% compared to CNY 330,126,718.06 in 2023[19]. - The net profit attributable to shareholders for 2024 was a loss of CNY 10,375,438.31, an improvement of 87.00% from a loss of CNY 79,791,984.63 in 2023[19]. - The net cash flow from operating activities improved to a negative CNY 82,489,277.85 in 2024, a 19.30% increase from a negative CNY 102,215,067.80 in 2023[19]. - The basic earnings per share for 2024 was -0.0106, showing an improvement of 87.90% from -0.0876 in 2023[19]. - Total assets at the end of 2024 were CNY 2,061,938,679.96, a 5.66% increase from CNY 1,951,543,466.24 at the end of 2023[19]. - The net assets attributable to shareholders decreased by 1.03% to CNY 1,405,606,183.20 at the end of 2024 from CNY 1,420,251,225.49 at the end of 2023[19]. - The company has reported a decrease in net profit after deducting non-recurring gains and losses, with a loss of CNY 151,674,390.39 in 2024 compared to a loss of CNY 115,760,381.59 in 2023, a decline of 31.02%[19]. Cash Flow and Investment - The company reported a significant difference between net cash flow from operating activities and net profit, with a net cash flow of -¥82,489,277.85 and a net profit of -¥11,466,500[83]. - Investment income amounted to ¥143,019,379.11, representing 1,223.17% of total profit, primarily from equity investment disposals and equity method accounting for joint ventures[85]. - Fair value changes resulted in a gain of ¥6,340,000.00, accounting for 54.22% of total profit, mainly from the fair value changes of held financial assets[85]. - Cash and cash equivalents decreased by 25.65% to ¥451,840,676.26, down from ¥928,057,174.89, due to cash management of temporarily idle raised funds[87]. - The company raised a total of RMB 794,483,087.84 through the issuance of 80,413,268 shares at a price of RMB 9.88 per share[97]. - The company has not yet utilized the remaining funds for temporary liquidity support, which are currently held in a demand deposit account[98]. Digital Healthcare Initiatives - The company is focused on digital healthcare, emphasizing the integration of AI and big data in its services to enhance medical insurance fund management and healthcare quality[30]. - The digital medical insurance business aims to provide standardized and intelligent support systems for medical insurance payment and supervision, enhancing the efficiency of fund utilization[30]. - The company is actively involved in the development of a multi-level medical security system, aligning with national healthcare reforms to improve service delivery[29]. - The introduction of DRG payment services is designed to optimize the payment process for medical institutions, promoting better resource allocation and efficiency[31]. - The company is leveraging AI and big data to establish a disease classification system that supports local healthcare needs and enhances payment accuracy[32]. Research and Development - The company is focusing on upgrading its R&D center, which includes the first and second phases of data platform upgrades, aiming to enhance AI-based medical knowledge graphs and support various business R&D efforts[76]. - The number of R&D personnel decreased by 25.35% from 651 in 2023 to 486 in 2024[77]. - R&D investment amount decreased by 39.16% from ¥49,062,327.32 in 2023 to ¥29,849,857.42 in 2024[78]. - The proportion of R&D investment to operating revenue fell by 6.50% from 14.86% in 2023 to 8.36% in 2024[78]. Corporate Governance and Management Changes - The company has a complete and independent organizational structure, ensuring no mixed operations with controlling shareholders[126]. - The company appointed Yuan Hongquan as the new General Manager on April 25, 2024, after he transitioned from the position of Deputy General Manager[131]. - The company experienced a management change with the resignation of several executives, including Sun Di Cao and Sun Li Qun, due to personal reasons[131]. - The company’s board of directors held a meeting on April 25, 2024, to approve the management changes and discuss future strategies[131]. - The company has engaged in multiple investor communications throughout 2024 to discuss overall performance and future business plans[117]. Environmental and Social Responsibility - The company has published its 2024 ESG report detailing its social responsibility initiatives[173]. - The company is not classified as a key pollutant discharge unit by environmental protection authorities[171]. - No administrative penalties were imposed on the company or its subsidiaries for environmental issues during the reporting period[171]. - The company has taken measures to reduce carbon emissions, although specific details were not disclosed[172]. Market Expansion and Strategic Focus - The company has identified key areas for market expansion, particularly in health services, aiming for a 20.7% growth in this segment[101]. - The company is exploring potential acquisitions to enhance its service offerings and market presence, with a focus on strategic partnerships[101]. - The company aims to transform into a leading health data service provider by leveraging information technology, digitalization, and AI models to enhance customer value[112]. - The strategic focus includes implementing a "smart innovation" strategy to become a data-driven enterprise in the healthcare sector, particularly in the "three medical" fields[112]. Financial Management and Compliance - The company has established a financial service agreement with Guoxin Group Financial Co., Ltd. to handle daily fund settlements, deposits, and loans, which was approved in the board meeting on May 21, 2024[198]. - The maximum daily deposit limit with Guoxin Group Financial Co., Ltd. is RMB 50 million, with an interest rate of 0.525%[195]. - The company has not engaged in any significant related party transactions during the reporting period[191]. - The company has not experienced any major litigation or arbitration matters during the reporting period[189].